Your browser doesn't support javascript.
loading
ABSTRACT
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
Sujet(s)
Mots clés
Texte intégral: 1 Indice: WPRIM Sujet Principal: Thrombose / Endoprothèses / Maladie coronarienne / Endoprothèses à élution de substances / Libération de médicament / Corée Type d'étude: Clinical_trials / Guideline Limites du sujet: Humans Pays comme sujet: Asia langue: En Texte intégral: Korean Circulation Journal Année: 2017 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Thrombose / Endoprothèses / Maladie coronarienne / Endoprothèses à élution de substances / Libération de médicament / Corée Type d'étude: Clinical_trials / Guideline Limites du sujet: Humans Pays comme sujet: Asia langue: En Texte intégral: Korean Circulation Journal Année: 2017 Type: Article